Format

Send to

Choose Destination
Cent Eur J Immunol. 2017;42(3):281-286. doi: 10.5114/ceji.2017.70972. Epub 2017 Oct 30.

Evaluation of the adenosine deaminase (ADA) G22A gene polymorphism with recurrent spontaneous abortion among Egyptian patients.

Author information

1
Department of Clinical and Chemical Pathology, Faculty of Medicine, Beni-Suef University Cairo, Egypt.

Abstract

Introduction:

Adenosine and deoxyadenosine metabolism is influenced by adenosine deaminase (ADA) enzyme. ADA increases in different diseases and is considered as one of the markers for cell-mediated immunity. Pregnancy is associated with depressed cell-mediated immunity. The level of ADA expression, which seems to play a key role in maintaining pregnancy, is influenced by adenosine deaminase G22A gene polymorphism. We aimed in our study to evaluate the association of ADA G22A gene polymorphism with recurrent spontaneous abortion (RSA) in Egyptian women.

Material and methods:

Adenosine deaminase G22A gene polymorphism was genotyped in 40 patients (age range 22-39 years) with a history of RSA, selected from those attending the Gynaecology and Obstetrics Clinic of Beni-Suef University Hospital, and 20 age-matched healthy women as a control group, using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.

Results:

In our study, no statistically significant difference was found between RSA patients and control group as regards ADA G22A genotypes (p = 0.653) and alleles (p = 0.697). A comparison of the frequencies of ADA alleles in RSA patients as regards the below-35-years-old age group revealed that ADA 2(A) allele was associated with a low risk for RSA in patients aged 35 years old or younger (p = 0.008).

Conclusions:

In conclusion, our study revealed an age-dependent protective value of ADA 2(A) allele in recurrent spontaneous abortions among the Egyptian population.

KEYWORDS:

ADA; ADA G22A gene polymorphism; PCR-RFLP; Recurrent spontaneous abortion

Conflict of interest statement

The authors declare no conflicts of interest to declare.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center